Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.

Orthocell has entered an MOU to secure exclusive distribution rights for Marine Biomedical's innovative bone substitute PearlBone, and lift its stake in the company to 12 per cent.